SC3 - Secure, clean and efficient energy

About this programme

The Energy Challenge is designed to support the transition to a reliable, sustainable and competitive energy system.

To make the transition to a competitive energy system, we need to overcome a number of challenges, such as increasingly scarce resources, growing energy needs and climate change.

The Energy Challenge is structured around seven specific objectives and research areas:

  • Reducing energy consumption and carbon footprint
  • Low-cost, low-carbon electricity supply
  • Alternative fuels and mobile energy sources
  • A single, smart European electricity grid
  • New knowledge and technologies
  • Robust decision making and public engagement
  • Market uptake of energy and ICT innovation.
Click to read more 
Hide text 

Your NCP contact for this programme

Image of Ria De Breucker

Ria De Breucker

Ria.debreucker@vlaio.be

+32 2 553 13 77

Your PC contact for this programme

Find the contact info on the site of WEWIS

The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.

The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.

Latest news

Upcoming events

No events that are specifically related to SC3 - Secure, clean and efficient energy were found. Check the full calendar.

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.